Friday, February 22, 2013
Mercy Corps Action Center Event Space
View map
12:00 pm to 1:30 pm
In July 2012 the Food and Drug Administration approved the use of Truvada, a commonly prescribed HIV antiretroviral medication, for use as pre-exposure prophylaxis (PrEP) against HIV.
The topic of PrEP has inspired much discussion and controversy among medical and social service providers, advocacy groups, and the community at large. How effective is PrEP? What is the science behind it? How practical is PrEP at the community level? And what do providers and people at risk for HIV who are interested in PrEP need to know? 
This lunchtime panel presentation and discussion will include an overview of the science behind PrEP, including clinical trials, a look at how it is being rolled out in other cities, and the resources available to both providers and the community around PrEP.
Panelists include Joanne Stekler, MD, MPH, Assistant Professor, University of Washington Division of Allergy & Infectious Diseases, Deputy Director, Public Health Seattle & King County HIV/STD Program Harborview Medical Center and James Shean, Director, Managed Markets, Gilead Sciences.
Providers, clients, and community partners are welcome to attend; doors open at 11:30am.  Light refreshments and networking time included.

What's New in HIV?